Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Moderna Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income (loss) (3,630) (1,380) 79 1,465 1,043 2,197 3,657 4,868 3,333 2,780 1,221 (272) (234) (117) (124) (123) (123) (135) (133)
Stock-based compensation 77 74 75 62 70 50 44 37 40 35 30 25 23 24 20 20 21 21 18
Depreciation and amortization 249 92 78 80 113 76 79 78 70 69 15 8 9 8 7 9 7 7 7
Leased assets expensed 62
Amortization/accretion of investments (12) (12) (17) (4) 6 11 18 21 20 8 5 5 3 1 1 (1) (1) (1)
(Gain) loss on equity investments, net 33 (35) 18
Deferred income taxes 1,464 (220) (310) (86) (97) (230) (146) (229) (17) (22) (50)
Other non-cash items 37 (8) (4) (8) 21 15
Accounts receivable, net (1,634) 881 272 1,310 (4) 483 1 (33) (1,122) 1,190 (1,819) (1,200) (157) (26) (2) 3 (4) 2 6
Prepaid expenses and other assets 914 70 (212) (1,030) (345) 90 (414) (303) (76) (98) (12) (173) (56) (7) (4) 8 (4) 3 3
Inventory 228 18 216 1,128 (156) 21 (501) (476) (322) (148) (448) (47)
Right-of-use assets, operating leases (648) (13) 4 (8) 9 10 10 (33) (11) (16) 2 3 (1) 2 (14) 2 (4) (5) 2
Accounts payable 179 (70) (117) 151 145 (21) (35) 178 (18) 59 (15) (2) 2 9 2 (5) (18) (3) 2
Accrued liabilities 696 (138) (495) 258 49 191 114 389 233 82 285 256 112 33 (13) 5 20 5 (33)
Deferred revenue (194) (160) (819) (1,466) (321) (1,565) (805) (1,607) 998 (233) 3,666 2,602 1,189 52 (11) (10) (7) (16)
Income taxes payable 9 (19) 18 (18) (283) (1,243) 716 311 565
Operating lease liabilities 593 8 4 13 (8) (9) (10) 9 10 (2) (3) (1) 15 (1) 10 5 (2)
Other liabilities 39 (3) (15) (185) 10 228 35 100 (417) 347 93 (1) 2 (1) 6 (6) (1) 1
Changes in assets and liabilities, net of acquisition of business 182 574 (1,144) 153 (904) (1,815) (889) (1,465) (170) 1,193 1,750 1,436 1,092 60 (10) (5) (11) (1) (37)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities 2,030 465 (1,304) 197 (791) (1,893) (894) (1,558) (57) 1,283 1,750 1,537 1,126 93 18 24 16 26 (12)
Net cash provided by (used in) operating activities (1,600) (915) (1,225) 1,662 252 304 2,763 3,310 3,276 4,063 2,971 1,264 893 (24) (106) (99) (107) (109) (144)
Purchases of marketable securities (816) (196) (1,085) (2,510) (191) (3,162) (5,572) (2,373) (3,720) (5,833) (726) (630) (1,423) (282) (621) (196) (106) (414) (430)
Proceeds from maturities of marketable securities 1,447 1,904 1,360 929 813 968 441 263 215 521 339 389 231 247 270 245 184 160 404
Proceeds from sales of marketable securities 298 470 1,957 630 412 1,129 1,377 1,122 277 1,464 242 74 32 66 42 88 42 18 21
Purchases of property, plant and equipment (140) (234) (113) (92) (89) (87) (132) (120) (99) (30) (35) (23) (19) (19) (6) (7) (7) (11) (8)
Acquisition of business, net of cash acquired (85)
Investment in convertible notes and equity securities (23) (5) (35) (30)
Net cash (used in) provided by investing activities 789 1,944 2,011 (1,048) 945 (1,152) (3,921) (1,138) (3,327) (3,878) (180) (190) (1,178) 12 (316) 130 113 (247) (12)
Proceeds from public offerings of common stock, net of issuance costs 1,303 549
Proceeds from issuance of common stock through equity plans 6 16 9 25 11 17 12 28 32 36 28 50 30 78 28 31 16 4
Repurchase of common stock, including excise tax 1 (628) (526) (402) (1,006) (1,298) (623) (857)
Changes in financing lease liabilities (65) (56) (25) (61) (46) (46) (31) (44) (34) (60) (2) (6)
Net cash provided by (used in) financing activities (58) (668) (542) (438) (1,041) (1,327) (642) (873) (2) (24) 26 44 30 1,381 578 31 16 4
Net increase (decrease) in cash, cash equivalents and restricted cash (869) 361 244 176 156 (2,175) (1,800) 1,299 (53) 161 2,817 1,118 (256) 1,370 156 62 22 (351) (156)

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Moderna Inc. net cash provided by (used in) operating activities increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Moderna Inc. net cash (used in) provided by investing activities decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Moderna Inc. net cash provided by (used in) financing activities decreased from Q1 2023 to Q2 2023 but then increased from Q2 2023 to Q3 2023 exceeding Q1 2023 level.